TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 1.20nMAssay Description:KINOMEscan (Ambit Biosciences, San Diego, Calif.), a high-throughput method for screening small molecular agents against a large panel of human kinas...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 2.30nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 5nMAssay Description:Competition binding assay was used to measure the interaction between the phage-tagged kinase, immobilized competitive ligand, and unlinked test comp...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 6.30nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 27nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 40nMAssay Description:Competition binding assay was used to measure the interaction between the phage-tagged kinase, immobilized competitive ligand, and unlinked test comp...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 42nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 68nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 78nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 140nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 160nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 190nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 200nMAssay Description:Competition binding assay was used to measure the interaction between the phage-tagged kinase, immobilized competitive ligand, and unlinked test comp...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 260nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 450nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 550nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 590nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 600nMAssay Description:Competition binding assay was used to measure the interaction between the phage-tagged kinase, immobilized competitive ligand, and unlinked test comp...More data for this Ligand-Target Pair
Affinity DataKd: 600nMAssay Description:Competition binding assay was used to measure the interaction between the phage-tagged kinase, immobilized competitive ligand, and unlinked test comp...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 630nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 860nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 1.70E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 1.80E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 2.80E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 3.20E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Dana-Farber Cancer Institute
US Patent
Dana-Farber Cancer Institute
US Patent
Affinity DataKd: 3.40E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 6.00E+3nMAssay Description:Competition binding assay was used to measure the interaction between the phage-tagged kinase, immobilized competitive ligand, and unlinked test comp...More data for this Ligand-Target Pair
Affinity DataKd: >1.00E+4nMAssay Description:Competition binding assay was used to measure the interaction between the phage-tagged kinase, immobilized competitive ligand, and unlinked test comp...More data for this Ligand-Target Pair